Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors

• Published in: The Journal of steroid biochemistry and molecular biology Vol. 143; pp. 250 - 258
• Main Authors: Skarydova, Lucie, Hofman, Jakub, Chlebek, Jakub, Havrankova, Jana, Kosanova, Katerina, Skarka, Adam, Hostalkova, Anna, Plucha, Tomas, Cahlikova, Lucie, Wsol, Vladimir
• Format: Journal Article
• Language: English
• Published: England 01-09-2014
• Subjects: 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors; Aldo-Keto Reductase Family 1 Member C3; Berberine Alkaloids - pharmacology; Blotting, Western; Breast Neoplasms - drug therapy; Breast Neoplasms - enzymology; Breast Neoplasms - pathology; Cell Proliferation; Cell Survival - drug effects; Chromatography, High Pressure Liquid; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - enzymology; Colorectal Neoplasms - pathology; Enzyme Inhibitors - pharmacology; Female; Humans; Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors; Testosterone - metabolism; Tumor Cells, Cultured; AKR1C3; Isoquinoline; Alkaloids; Inhibitor; Natural; Cancer
• ISSN: 0960-0760; 1879-1220
• DOI: 10.1016/j.jsbmb.2014.04.005

AKR1C3 is an important human enzyme that participates in the reduction of steroids and prostaglandins, which leads to proliferative signalling. In addition, this enzyme also participates in the biotransformation of xenobiotics, such as drugs and procarcinogens. AKR1C3 is involved in the development of both hormone-dependent and hormone-independent cancers and was recently demonstrated to confer cell resistance to anthracyclines. Because AKR1C3 is frequently upregulated in various cancers, this enzyme has been suggested as a therapeutic target for the treatment of these pathological conditions. In this study, nineteen isoquinoline alkaloids were examined for their ability to inhibit a recombinant AKR1C3 enzyme. As a result, stylopine was demonstrated to be the most potent inhibitor among the tested compounds and exhibited moderate selectivity towards AKR1C3. In the follow-up cellular studies, stylopine significantly inhibited the AKR1C3-mediated reduction of daunorubicin in intact cells without considerable cytotoxic effects. This inhibitor could therefore be used as a model AKR1C3 inhibitor in research or evaluated as a possible therapeutic anticancer drug. Furthermore, based on our results, stylopine can serve as a model compound for the design and future development of structurally related AKR1C3 inhibitors.